SGLT2 inhibitor

Top 3 new drug approvalsHere are 3 of the top new drug approvals in late December and early January.
New therapies show promise in treating diabetes
New therapies show promise in treating diabetesNew updates in insulin products, as well as non-pharma therapies are on the horizon for diabetes.
Serious risks associated with SGLT2 inhibitorsFDA is warning about ketoacidosis and urinary tract infections associated with the relatively new class of type 2 diabetes medicines called sodium-glucose cotransporter-2 (SGLT2) inhibitors such as Invokana and Jardiance.
FDA increases warning on diabetes medicationThe FDA has strengthened its warning for the type 2 diabetes medicine canagliflozin (Invokana, Invokamet) related to the increased risk of bone fractures, and added new information about decreased bone mineral density.
SGLT2 inhibitors: New drug therapy for type 2 diabetes may carry acidosis riskFDA has issued a warning about a possible link between use of SGLT2 inhibitors and ketoacidosis.
SGLT2 inhibitors for diabetes may cause ketoacidosis, FDA warnsThe FDA is warning that the type 2 diabetes medicines canagliflozin, dapagliflozin, and empagliflozin may lead to ketoacidosis, a serious condition where the body produces high levels of blood acids called ketones that may require hospitalization.
What's on the horizon for diabetes therapy?SGLT2 inhibitors, GLP-1 receptor agonists, inhaled insulin, extended-release treatments, and fixed-dose combination therapies are among the approaches that have emerged to treat the exploding numbers of type 2 diabetes patients.
FDA approves combo pill for adults with type 2 diabetesFDA has approved once-daily dapagliflozin and metformin hydrochloride extended-release (Xigduo, AstraZeneca) (XR) for the treatment of adults with type 2 diabetes. Xigduo XR is indicated as an adjunct therapy to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both dapagliflozin and metformin is appropriate.
Another SGLT2 inhibitor for type 2 diabetes is approvedFDA has approved empagliflozin (Jardiance, Boehringer Ingelheim Pharmceuticals) as another option for adult patients with type 2 diabetes.